Five-year overall survival (OS) and OS by baseline liver function from the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

被引：0
|
作者：
Kudo, M. [1 ]
Rimassa, L. [2 ]
Chan, S. L. [3 ]
Sangro, B. [4 ,5 ,6 ]
Lau, G. [7 ]
Breder, V. V. [8 ]
Varela, M. [9 ]
Crysler, O. V. [10 ]
Bouattour, M. [11 ]
Dao, V. T. [12 ]
Faccio, A. [13 ]
Furuse, J. [14 ]
Jeng, L-B. [15 ]
Kang, Y-K. [16 ]
Kelley, R. K. [17 ]
Paskow, M. J. [18 ]
Makowsky, M. [19 ]
Ran, D. [20 ]
Negro, A. [19 ]
Abou-Alfa, G. K. [21 ,22 ]
机构：
[1] Kindai Univ, Fac Med, Dept Gastroenterol & Hepatol, Osaka, Japan
[2] Humanitas Univ, Pieve Emanuele & Humanitas Canc Ctr, IRCCS Humanitas Res Hosp, Dept Biomed Sci, Milan, Italy
[3] Chinese Univ Hong Kong, State Key Lab Translat Oncol, Dept Clin Oncol, Sir Yue Kong Pao Ctr Canc, Hong Kong, Peoples R China
[4] Clin Univ Navarra, Liver Unit, Pamplona, Spain
[5] Clin Univ Navarra, HPB Oncol Area, Pamplona, Spain
[6] CIBEREHD, Pamplona, Spain
[7] Humanity & Hlth Med Grp, Humanity & Hlth Clin Trial Ctr, Hong Kong, Peoples R China
[8] NN Blokhin Natl Med Res Ctr Oncol, Dept Chemotherapy, Moscow, Russia
[9] Univ Oviedo, Liver Unit, Hosp Univ Cent Asturias, IUOPA,ISPA,FINBA, Oviedo, Spain
[10] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI USA
[11] Hop Beaujon, AP HP, Liver Canc Unit, Paris, France
[12] Natl Canc Hosp, Canc Res & Clin Trials Ctr, Dept Optimal Therapy, Hanoi, Vietnam
[13] CEON Ctr Especializado Oncol, Dept Oncol, Ribeirao Preto, Brazil
[14] Kanagawa Canc Ctr, Dept Gastroenterol, Tokyo, Japan
[15] China Med Univ & Hosp, Dept Surg, Taichung, Taiwan
[16] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[17] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[18] AstraZeneca, Global Med Affairs, Gaithersburg, MD USA
[19] AstraZeneca, Oncol R&D, Late Stage Dev, Gaithersburg, MD USA
[20] AstraZeneca, Stat, Gaithersburg, MD USA
[21] Cornell Univ, Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[22] Cornell Univ, Weill Med Coll, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.151
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1270
引用
收藏
页码：S1451 / S1452
页数：3
相关论文
共 50 条
  • [1] Five-year overall survival (OS) and OS by tumour response measures from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
    Rimassa, L.
    Chan, S. L.
    Sangro, B.
    Lau, G.
    Kudo, M.
    Breder, V.
    Varela, M.
    Crysler, O.
    Bouattour, M.
    Dao, V. T.
    Faccio, A.
    Furuse, J.
    Jeng, L-B.
    Kang, Y-K.
    Kelley, R. K.
    Paskow, M. J.
    Makowsky, M.
    Ran, D.
    Negro, A.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2024, 35 : S656 - S656
  • [2] Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
    Chan, S. L.
    Sangro, B.
    Kelley, R. K.
    Lau, G.
    Kudo, M.
    Sukeepaisarnjaroen, W.
    De Toni, E. N.
    Furuse, J.
    Kang, Y-K.
    Galle, P. R.
    Rimassa, L.
    Heurgue, A.
    Tam, V. C.
    Dao, T. V.
    Thungappa, S. Chiradoni
    Breder, V.
    Ostapenko, Y. V.
    Reig Monzon, M. E.
    Gupta, C.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1530 - S1531
  • [3] Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
    Sangro, Bruno
    Chan, Stephen L.
    Kelley, Katie
    Lau, George
    Kudo, Masatoshi
    Sukeepaisarnjaroen, Wattana
    De Toni, Enrico
    Furuse, Junji
    Kang, Yoon-Koo
    Galle, Peter R.
    Rimassa, Lorenza
    Heurgue, Alexandra
    Tam, Vincent C.
    Dao, Tu Van
    Thungappa, Satheesh Chiradoni
    Breder, Valeriy
    Ostapenko, Yuriy
    Reig, Maria
    Makowsky, Mallory
    Gupta, Charu
    Negro, Alejandra
    Abou-Alfa, Ghassan
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 69 - 70
  • [4] FIVE-YEAR OVERALL SURVIVAL AND OVERALL SURVIVAL BY TUMOR RESPONSE MEASURES FROM THE PHASE 3 HIMALAYA STUDY OF TREMELIMUMAB PLUS DURVALUMAB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA
    Rimassa, Lorenza
    Chan, Stephen
    Sangro, Bruno
    Lau, George
    Kudo, Masatoshi
    Breder, Valeriy
    Varela, Maria
    Crysler, Oxana
    Bouattour, Mohamed
    Tu Van Dao
    Faccio, Adilson
    Furuse, Junji
    Jeng, Long-Bin
    Kang, Yoon Koo
    Kelley, Robin Kate
    Paskow, Michael
    Makowsky, Mallory
    Ran, Di
    Negro, Alejandra
    Abou-Alfa, Ghassan
    HEPATOLOGY, 2024, 80
  • [5] Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
    Chan, L. S.
    Kudo, M.
    Sangro, B.
    Kelley, R. K.
    Furuse, J.
    Park, J-W.
    Sunpaweravong, P.
    Fasolo, A.
    Yau, T.
    Kawaoka, T.
    Cheng, A-L.
    Azevedo, S.
    Reig Monzon, M. E.
    Assenat, E.
    Yarchoan, M.
    He, A. R.
    Makowsky, M.
    Ran, D.
    Negro, A.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S869 - S870
  • [6] Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
    Chan, S. L.
    Kudo, M.
    Sangro, B.
    Kelley, R. K.
    Furuse, J.
    Park, J-W.
    Sunpaweravong, P.
    Fasolo, A.
    Yau, T.
    Kawaoka, T.
    Cheng, A-L.
    Azevedo, S.
    Reig Monzon, M. E.
    Assenat, E.
    Yarchoan, M.
    He, A. R.
    Makowsky, M.
    Gupta, C.
    Negro, A.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2022, 33 : S1456 - S1456
  • [7] Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
    Chan, S. L.
    Kudo, M.
    Sangro, B.
    Kelley, R. K.
    Furuse, J.
    Park, J-W.
    Sunpaweravong, P.
    Fasolo, A.
    Yau, T.
    Kawaoka, T.
    Cheng, A-L.
    Azevedo, S.
    Reig Monzon, M. E.
    Assenat, E.
    Yarchoan, M.
    He, A. R.
    Makowsky, M.
    Gupta, C.
    Negro, A.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2022, 33 : S1456 - S1456
  • [8] Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
    Chan, S. L.
    Kudo, M.
    Sangro, B.
    Kelley, R. K.
    Furuse, J.
    Park, J-W.
    Sunpaweravong, P.
    Fasolo, A.
    Yau, T.
    Kawaoka, T.
    Cheng, A-L.
    Azevedo, S.
    Reig Monzon, M. E.
    Assenat, E.
    Yarchoan, M.
    He, A. R.
    Makowsky, M.
    Ran, D.
    Negro, A.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2022, 33 : S1465 - S1466
  • [9] Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
    Sangro, B.
    Chan, S. L.
    Kelley, R. K.
    Lau, G.
    Kudo, M.
    Sukeepaisarnjaroen, W.
    Yarchoan, M.
    De Toni, E. N.
    Furuse, J.
    Kang, Y. K.
    Galle, P. R.
    Rimassa, L.
    Heurgue, A.
    Tam, V. C.
    Van Dao, T.
    Thungappa, S. C.
    Breder, V.
    Ostapenko, Y.
    Reig, M.
    Makowsky, M.
    Paskow, M. J.
    Gupta, C.
    Kurland, J. F.
    Negro, A.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2024, 35 (05) : 448 - 457
  • [10] Outcomes by comorbidities (CMs) with tremelimumab (T) and durvalumab (D) in the phase III HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)
    Rimassa, L.
    Dayyani, F.
    Kelley, R. K.
    Sangro, B.
    Chan, S. L.
    Mccoy, C. L.
    Paskow, M. J.
    Makowsky, M.
    Gupta, C.
    Ran, D.
    Negro, A.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2024, 35 : S77 - S78
12345